Piper Jaffray Upgrades Genomic Health, Downgrades BD

The investment bank maintained its 12-month price targets on the respective stocks. It said that Genomic Health was trading at an "attractive entry point."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories